{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-150301","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.949369+00:00","generated_at":"2026-05-18T15:36:59.413602+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyra Therapeutics raises $5M upfront (up to $15M with warrant exercise) in equity offering","bullets":["Upfront gross proceeds of $5.0M from sale of 423,372 shares (or pre-funded warrants) at $11.81 per share+private warrant.","Additional up to $9.8M if private warrants (846,744 shares at $11.56) exercised fully; warrants expire 24 months after resale registration effective.","Net proceeds ~$4.3M after placement agent fees (7% cash fee plus 6.5% on future warrant exercises).","Proceeds to be used for working capital and potential clinical development/manufacturing of LYR-210 for chronic rhinosinusitis.","Company previously terminated ~87 employees after failed ENLIGHTEN 1 Phase 3 trial and faces going concern risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-150301","json":"https://secwatch.observer/filing/0001193125-25-150301.json","markdown":"https://secwatch.observer/filing/0001193125-25-150301.md","text":"https://secwatch.observer/filing/0001193125-25-150301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525150301/0001193125-25-150301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525150301/d75821d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T15:36:59.413602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}